Kura Oncology Q4 net loss widens on higher R&D spend

Kura Oncology

05/03/2026 11:41

Corrects collaboration revenue in Key Details table to $15.20 mln from $2.13 mln

Overview

Biopharmaceutical firm reported $2.1 mln in Q4 net product revenue from KOMZIFTI launch

Company's Q4 net loss widened to $81 mln, driven by increased R&D expenses

Kura Oncology maintains strong cash position, expected to fund operations into late 2027

Outlook

Kura anticipates topline Phase 3 results for ziftomenib in 2028

Result Drivers

KOMZIFTI LAUNCH - KOMZIFTI generated $2.1 mln in Q4 revenue, with rapid payer coverage and positive market feedback supporting its adoption in R/R NPM1-m AML

Company press release: ID:nGNX680pl7

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration Revenue
$15.20 mln
Q4 EPS
-$0.92
Q4 Net Income
-$81 mln
Q4 Operating Expenses
$103.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Kura Oncology Inc is $28.00, about 227.5% above its March 4 closing price of $8.55

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)